Quick answer
Hexarelin is a synthetic hexapeptide of the growth-hormone-releasing-peptide (GHRP) family, with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 and a mass of about 887 Da, used in research as a potent, less selective agonist of the ghrelin receptor (GHS-R1a).
- Class: GHRP-family hexapeptide with two D-amino acids that resist proteolysis; differs from GHRP-6 by one methyl group
- Targets in models: GHS-R1a (Gq/phospholipase-C/calcium signaling) and, in cardiac tissue, the scavenger receptor CD36
- Why it is used: a strong-agonist benchmark against selective secretagogues such as ipamorelin
- Handling: two tryptophans make it light- and oxidation-sensitive; use low-binding labware and the reconstitution calculator for mg/mL stock math
- Available as: hexarelin research vials, with lot data on the COA page
Hexarelin occupies a particular place in secretagogue research. It is old enough to have shaped the field, potent enough to serve as a benchmark, and non-selective enough to be informative about what selectivity means. This guide gathers its history, chemistry, receptor pharmacology, preclinical model systems, handling and quality documentation in one place. For laboratory research use only; not for human consumption. The discussion concerns assays, cell preparations and animal models only; receptor-level observations do not translate into statements about physiological outcomes in any other setting.
What hexarelin is
Hexarelin is a synthetic hexapeptide belonging to the growth-hormone secretagogue family. It is one of the more potent agonists of the growth-hormone-secretagogue receptor studied in research, and it is frequently used as a strong-agonist reference within the class. Its engineered residues give it both high potency and resistance to enzymatic breakdown, and its compact six-residue architecture makes it a well-defined molecule for laboratory characterization.
Two features distinguish it from more narrowly acting peptides. At the pituitary it acts at GHS-R1a, the same receptor engaged by the selective agonist ipamorelin, but with lower selectivity and measurable effects on other pituitary readouts. Outside the pituitary, preclinical work describes interaction with CD36 in cardiovascular tissue models, which opens a research question that most growth-hormone secretagogues cannot address. This dual profile is the reason it is used as a probe for selectivity.
The compound is introduced on the site's hexarelin research overview, compared directly with its closest relative in hexarelin vs ipamorelin, and listed on the hexarelin product page.
Discovery and history
Hexarelin belongs to the first generation of synthetic growth-hormone secretagogues, designed in the late 1980s and 1990s to trigger growth-hormone release by a route distinct from growth-hormone-releasing hormone (GHRH). Its development helped define an entire class of research tools.
Roots in the GHRP series
The lineage traces to early growth-hormone-releasing peptides derived from studies of enkephalin-like sequences that unexpectedly stimulated growth-hormone release in vitro (reference 1). Iterative structure-activity work produced a series of hexapeptides, among them GHRP-6, and hexarelin emerged as one of the most potent, becoming a benchmark for the class.
A tool that revealed a receptor
One of hexarelin's most important historical contributions was as a pharmacological probe. Because these synthetic secretagogues did not act through the GHRH receptor, the search to explain them pointed to an orphan receptor, cloned in the mid-1990s (reference 2), which was later matched to its endogenous ligand, ghrelin (reference 3). In this way hexarelin and its relatives helped illuminate a receptor system that reshaped growth-hormone-axis research.
Reading older literature
Synthetic GHRPs were investigated before ghrelin was identified, so early reports often describe an unnamed secretagogue receptor without today's terminology. Modern readers should map those terms carefully and distinguish evidence available at the time from later receptor assignments.
Comparison with GHRH analogs
Because hexarelin acts at the ghrelin/secretagogue receptor and not at the GHRH receptor, it has long been studied beside GHRH-based analogs such as sermorelin, which lets researchers dissect two complementary arms of the same axis. Hexarelin remains a reference secretagogue because its long history has produced a well-understood pharmacological profile. A shorter account is on the discovery and history page.
Chemical structure and synthesis
Hexarelin is a hexapeptide with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 and a theoretical average mass of about 887 Da. It differs from GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) by a single methyl group on the indole of the D-tryptophan, a change reported to increase stability and potency.
| Property | Hexarelin | Why it matters in the lab |
|---|---|---|
| Length | 6 residues | Suits stepwise solid-phase synthesis |
| Sequence | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 | Reference for identity confirmation |
| Non-natural features | Two D-amino acids; 2-methyl-tryptophan; C-terminal amide | Resistance to proteases and conformational rigidity |
| Theoretical mass | About 887 Da | Target value for mass spectrometry; 14 Da above GHRP-6 |
| Aromatic content | Two tryptophans and one D-phenylalanine | Relatively hydrophobic for its size; light- and oxidation-sensitive |
A GHRP-family pharmacophore
The D-configured residues and modified aromatic groups present a pharmacophore recognized by the ghrelin/growth-hormone-secretagogue receptor. The D-amino acids are a deliberate design choice: they disrupt recognition by common proteases and extend functional lifetime in assay media. A natural peptide of this size would normally be cleaved rapidly. The same stability logic appears in related compounds such as ipamorelin. For a primer on how residue order and configuration define a peptide, see understanding amino acid sequences.
Solid-phase synthesis and purification
The chain is assembled residue by residue on a resin support, cleaved, purified and lyophilized (see what is lyophilization) to yield a stable powder. Non-natural residues can complicate coupling, so careful chromatographic purification is needed to separate the target from truncated or deletion sequences.
Sequence-related impurities and material attributes
Synthesis does not produce only the intended chain. Incomplete coupling leaves deletion variants, and side reactions during deprotection or cleavage create closely related impurities, so the full chromatogram, the integration method and the mass result all deserve review. Salt form, residual moisture and counterions change measured mass and solubility without altering the sequence, which affects concentration calculations. Recording these attributes alongside purity and identity reduces avoidable variation between lots. Identity is confirmed by mass spectrometry against the expected value, as outlined in HPLC vs mass spectrometry. The extended discussion is in the chemical structure and synthesis article.
Mechanism of action
The proposed mechanism centers on GHS-R1a, the growth-hormone-secretagogue receptor now known as the ghrelin receptor. The pathway is detailed in the mechanism of action article.
Ghrelin-receptor engagement
GHS-R1a is a G-protein-coupled receptor. In model systems its activation by hexarelin is associated with the phospholipase-C pathway and intracellular calcium mobilization, the cascade linked to growth-hormone release from pituitary cells. Hexarelin is noted for high potency and comparatively lower receptor selectivity than ipamorelin; in pituitary cell cultures and animal models it is reported to produce meaningfully more cortisol and prolactin co-release, which is the main reason the two are run as comparators.
Beyond the pituitary receptor
Preclinical literature notes that hexarelin can interact with additional binding sites, including the scavenger receptor CD36 in cardiac tissue (reference 4). This broader profile is part of why hexarelin is used to probe secretagogue selectivity, distinguishing effects mediated by GHS-R1a from those attributed to other targets.
Complementary to GHRH analogs
Ghrelin-receptor agonists differ mechanistically from GHRH-receptor analogs such as sermorelin and CJC-1295 (no DAC), which raise cAMP through the GHRH receptor. Because both families converge on growth-hormone release through different receptors, they are often studied together to model signal integration; see CJC-1295 and ipamorelin in growth-hormone research for the analogous design with a selective agonist.
Signal integration in model systems
Growth-hormone release is not a single-receptor event in intact preparations. GHS-R1a signaling can interact with GHRH-receptor input and with inhibitory somatostatin tone, so the same agonist may give different readouts in isolated cells, tissue preparations and whole animals. Receptor binding, second-messenger assays and secretion measurements therefore answer related but non-equivalent questions.
Desensitization
Attenuation of the response after prolonged or repeated exposure has been described and is generally attributed to receptor desensitization. Time-course designs with washout intervals are used to study it.
Controls for mechanistic work
A strong design includes vehicle controls, a known GHS-R1a comparator and, where appropriate, a receptor antagonist or receptor-deficient model. Measuring both proximal signals such as calcium mobilization and downstream secretion helps separate receptor engagement from later pathway effects. Purity and identity should be documented, because closely related peptide impurities can distort potency comparisons.
Preclinical research findings
Preclinical characterization relies on cultured pituitary cell preparations, receptor-expressing cell lines, rodent models and isolated cardiac preparations. The table summarizes the systems and what each is used to read; the narrative version is in the preclinical research article.
| Model system | Typical readout | Main value | Key caution |
|---|---|---|---|
| Receptor-expressing cell lines | Intracellular calcium flux; inositol phosphate accumulation | Direct measure of GHS-R1a activation | Says nothing about pituitary secretion |
| Primary pituitary cultures | Growth-hormone release | Separates receptor-mediated effects from systemic influences | Culture conditions affect baseline responsiveness |
| Rodent endocrine models | Circulating biomarker changes; tissue molecular readouts | Integrates GHS-R1a, GHRH and somatostatin inputs | Species, age and baseline endocrine state alter responses |
| Isolated heart preparations | Functional recovery after ischemia-reperfusion | Tests cardiac effects outside the pituitary axis | Preparation-specific; not equivalent to whole animal |
| Rodent ischemia-reperfusion models | Tissue protection endpoints | Links cardiac findings to an intact organism | Endpoint timing and sampling schedules must be matched |
| Hypophysectomized or GH-deficient animals | Cardiac findings without pituitary input | Indicates effects that do not depend on GH release | Interpretation limited to the model used |
Receptor-mapping value
Work with hexarelin and its relatives helped define the secretagogue receptor system that was later matched to ghrelin, which makes it a historically important pharmacological tool whose value goes beyond its own profile.
Cardiovascular-model interest
A distinctive feature of the hexarelin literature is its cardiac work. Rodent ischemia-reperfusion and isolated-heart preparations are the principal systems. Notably, some of this work used hypophysectomized or GH-deficient animals, suggesting the cardiac findings do not depend on GH release, and binding studies have implicated CD36 in heart tissue as a second site of action alongside GHS-R1a (reference 4).
Comparative studies
Hexarelin commonly appears next to selective secretagogues like ipamorelin and GHRH analogs such as sermorelin. Benchmarking a potent, less selective agonist against a selective one is a standard way to interrogate receptor specificity. Related comparisons on the site include sermorelin vs ipamorelin and CJC-1295 vs ipamorelin.
Endpoints and reproducibility
Common endpoints include receptor-proximal signaling, pituitary secretion, circulating biomarkers in animal models and tissue-specific molecular readouts. Each operates on a different timescale with different confounders, so a study that maps receptor activation should not be read as establishing a later systemic effect. Species, age, tissue preparation, assay medium and baseline endocrine state all influence responses. Predefined controls, randomization and exclusion criteria, together with a report of the test article's chemical identity, make results comparable, and replication across complementary models is more informative than any single endpoint, particularly when separating GHS-R1a-mediated effects from CD36-associated observations.
Handling, reconstitution and storage
Tryptophan is the most photo-sensitive and oxidation-prone of the standard residues, and hexarelin carries two. Light protection therefore matters: amber vials or foil wrapping during handling, and minimal benchtop time, are sensible precautions. The D-amino acids make the peptide unusually resistant to proteolysis in assay media but do nothing for chemical oxidation. The two aromatic residues also make it relatively hydrophobic for its size, so it can adsorb to some plastics at low concentrations; low-binding tubes or glass are preferred for dilute working solutions. Compound notes are in hexarelin reconstitution and storage, and the full technique is in the lyophilized-peptide reconstitution guide.
Preparing the solution
Allow the vial to reach room temperature, use sterile technique, and add bacteriostatic water slowly down the inside wall rather than onto the cake (see bacteriostatic water explained). Dissolve by swirling; do not vortex or shake.
Concentration math
Stock concentration is vial mass divided by diluent volume. The values below are illustrative; the calculator accepts any combination and the calculator guide explains the inputs.
| Vial contents | Diluent added | Stock concentration |
|---|---|---|
| 5 mg | 1 mL | 5 mg/mL |
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
| 10 mg | 4 mL | 2.5 mg/mL |
Storage
The lyophilized powder is the most stable form and should be kept cold, dry and dark. For solutions, keep stock cold and protected from light, prepare fresh dilutions for each experiment where practical, and note the reconstitution date in the lab notebook with the lot number. Consistent labware across a comparator set reduces drift. General cold-chain principles are in storing research peptides. When hexarelin is run against ipamorelin or other GHRP-type compounds in binding studies, apply identical handling to every compound in the set.
Purity, COA and quality
Because closely related peptide impurities can distort potency comparisons, documentation is part of the experiment. Before a hexarelin lot enters an assay, a short checklist applies:
- Match the lot number on the vial to the certificate of analysis
- Confirm the HPLC purity figure is backed by an actual chromatogram
- Compare the observed mass with the theoretical value of about 887 Da
- Record the lot number, storage conditions and reconstitution date in the notebook
Keeping these details with the data lets an unexpected result be traced to the reagent, and lets another lab repeat the work with equivalent material. Batch documents are on the COA page; interpretation is covered in how to read a COA and understanding HPLC purity. Which impurities to look for is explained in hexarelin purity testing, and sourcing standards are in where to buy hexarelin for research. Current vials are on the product page.
Related compounds and comparisons
- Hexarelin vs ipamorelin contrasts the potent, less selective agonist with the selective one; the ipamorelin overview and product page cover the latter.
- Sermorelin vs ipamorelin and tesamorelin vs sermorelin frame the GHRH-receptor arm of the axis, where sermorelin is the reference analog.
- CJC-1295 DAC vs no-DAC and the CJC-1295 and ipamorelin blend show how GHRH analogs and ghrelin-receptor agonists are paired in model design.
As a rule, hexarelin is chosen when the aim is a robust, strong-agonist signal or a test of selectivity, and a selective comparator is chosen when the aim is to isolate GHS-R1a-mediated effects from off-target ones.
Frequently asked questions
How does hexarelin differ from ipamorelin?
Hexarelin is an older-generation agonist reported to be substantially more potent at stimulating GH release but less selective, with more cortisol and prolactin co-release than ipamorelin. Both act at GHS-R1a, which signals mainly through calcium mobilization in pituitary somatotrophs. See the comparison article.
What is hexarelin's structural class?
A synthetic hexapeptide of the GHRP family, like GHRP-6, engineered for greater potency. Its sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, differing from GHRP-6 by a methyl group on the D-tryptophan indole.
What is the molecular mass of hexarelin?
Approximately 887 Da, 14 Da above GHRP-6. This is the reference value for mass-spectrometric identity testing.
Has hexarelin been studied for anything beyond GH release?
Yes. Cardiac research using rodent ischemia-reperfusion and isolated-heart preparations is a distinct theme, and some of it was done in hypophysectomized or GH-deficient animals, suggesting independence from GH release. CD36 in heart tissue has been implicated as a second site of action.
Which assays measure GHS-R1a activation?
Intracellular calcium flux and inositol phosphate accumulation in receptor-expressing cell lines, plus GH release from primary pituitary cultures, are the standard in-vitro readouts.
Does the response change with repeated exposure?
Attenuation after prolonged or repeated exposure has been described in the literature and is generally attributed to receptor desensitization. Time-course designs with washout intervals are used to study it.
Why is light protection important?
Hexarelin contains two tryptophan residues, the most photo-sensitive and oxidation-prone of the standard amino acids. The D-amino acids guard against proteases, not against oxidation.
Why use low-binding labware?
The aromatic residues make the peptide relatively hydrophobic for its size, so it can adsorb to some plastics at low concentrations. Low-binding tubes or glass are preferred for dilute working solutions.
What documentation verifies a research-grade lot?
A lot-specific certificate of analysis with HPLC purity and mass-spectrometry identity confirmation; see hexarelin purity testing.
What controls does a hexarelin study need?
A vehicle-only condition prepared with identical diluent, a concentration series rather than a single level, replicates on separate days and, where possible, a reference compound with a known response run in parallel.
Research use and scope
For laboratory research use only; not for human consumption. Hexarelin is supplied for in-vitro and preclinical research by qualified investigators. The findings described belong to defined laboratory systems and do not extend to physiological or applied outcomes. Concentration figures are laboratory stock calculations only. Research vials are available from the hexarelin product page.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.
- Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844-849.